De La Motte Rouge T et al. HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA. ESMO Breast 2025;Abstract 412TiP.

Magbanua MJM et al. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun 2025;16(1):9945. Abstract

Magbanua M et al. CtDNA dynamics is most predictive of response in treatment-sensitive response-predictive subtypes of breast cancer: Results from the I-SPY2 trial. San Antonio Breast Cancer Symposium 2025;Abstract PD6-07.

McHayleh W et al. Clinical performance of Signatera genome assay for predicting recurrence in patients with breast cancer. San Antonio Breast Cancer Symposium 2025;Abstract PS2-07-26.

Medford AJ et al. Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+/HER2- early-stage breast cancer (LEADER). San Antonio Breast Cancer Symposium 2025;Abstract PD5-01.

Mukhtar R et al. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. ASCO 2025;Abstract 504.

Parsons HA et al. Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial. San Antonio Breast Cancer Symposium 2025;Abstract RF3-04.

Pusztai L et al. Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy. ASCO 2025;Abstract 1010.

Razavi P et al. Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC). ASCO 2025;Abstract 1011.